Sign up
Pharma Capital

Faron Pharma to expand its Clevegen trial to focus on Colorectal cancer

Faron Pharmaceuticals Ltd's (LON:FARN) chief executive Markku Jalkanen tells Proactive London's Andrew Scott they're to target more patients with late-stage colorectal cancer as part of the ongoing phase I/II study of its Clevegen immunotherapy drug.

One of the patients currently enrolled in the trial has the most common form of colorectal cancer – called MSI-low – and has seen a “significant shrinkage” in lung metastasis.

The cohort expansion stage is planned for later this year once the optimal dose has been identified.


View full FARN profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.